Rui Avelar Sells 27,904 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 27,904 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $24,434.20.

Evolus Trading Down 1.6 %

EOLS traded down $0.22 during trading hours on Thursday, reaching $13.25. The company’s stock had a trading volume of 663,321 shares, compared to its average volume of 593,757. Evolus, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The stock has a market cap of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The business’s 50-day moving average is $13.30 and its 200-day moving average is $13.92. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Wall Street Analysts Forecast Growth

EOLS has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Evolus by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock valued at $347,000 after purchasing an additional 1,094 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the period. Rhumbline Advisers raised its position in Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after purchasing an additional 1,762 shares during the period. Tradition Wealth Management LLC raised its position in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock valued at $144,000 after purchasing an additional 2,000 shares during the period. Finally, MetLife Investment Management LLC raised its position in Evolus by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after purchasing an additional 2,044 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.